Articles tagged with Prostate Cancer
Researchers at the University of Michigan have identified a potential new biomarker, sarcosine, that can distinguish between aggressive and non-aggressive prostate cancers. Sarcosine levels in urine may help predict cancer aggressiveness and identify patients who need aggressive treatment.
Researchers found that study methods and definitions of lead time significantly impact estimates of prostate cancer screening's effectiveness. The study suggests a need for clear methodology to accurately interpret findings.
Focal cryoablation, a minimally invasive treatment, is as effective as surgery in destroying diseased tumors and can be considered a first-line treatment for patients of all risk levels. The use of 3-D transperineal mapping biopsy heavily impacted how patients' disease was managed in 70 percent of cases.
Researchers at UIC will enroll 500 men with early-stage prostate cancer to investigate the biological factors behind poorer outcomes in obese patients. The study aims to identify new approaches to preventing prostate cancer recurrence or progression after treatment.
Researchers used a six-gene model to stratify patients with castration-resistant prostate cancer, predicting survival and accuracy rates. The study found the model accurate in predicting low-risk patients' survival and high-risk patients' mortality.
A new intervention being tested at Case Western Reserve University aims to improve the lives of men with incontinence problems from prostate cancer treatments. The 'Stay Dry' program combines pelvic floor muscle exercises with biofeedback techniques and therapy, and will be compared to standard care in a four-year study.
Researchers identified proepithelin as a protein that encourages cell growth and migration in prostate cancer cells, especially androgen-independent ones. Proepithelin overexpression may serve as a clinical marker for prostate cancer diagnosis and a therapeutic target.
The Society of Interventional Radiology will present research on treatments for kidney, prostate, bone cancer, herniated disks, and more at its 34th Annual Scientific Meeting. The meeting will showcase innovative interventional radiology studies and treatments.
The new guideline encourages healthy men to talk to their doctors about using 5-alpha reductase inhibitors (5-ARIs) to prevent prostate cancer, with a 25% relative risk reduction in most men. ASCO developed a Decision Aid Tool to help patients and families understand the risks and benefits of 5-ARIs.
Researchers found that PSA levels are more predictive of three-year prostate cancer risk in African-American men compared to Caucasian men with a family history. The study's findings suggest that PSA levels may be used to identify high-risk patients for earlier screening.
Research suggests that discontinuing routine PSA screening in elderly men (75+ years old) with low PSA levels may not increase undetected lethal disease rates. Instead, it could avoid unnecessary treatments and reduce diagnostic costs. Men over 75 with PSA < 3ng/ml have a low risk of developing high-risk prostate cancer.
A Johns Hopkins study found that older men with PSA levels less than 3 nanograms per milliliter are unlikely to die of or experience aggressive prostate cancer. This suggests that routine PSA testing may be unnecessary for some older men, potentially reducing costs and morbidity.
Researchers have identified a new biomarker for fatal prostate cancer, which is high levels of ionized serum calcium. Men with the highest levels of ionized serum calcium are three times more likely to die of prostate cancer than those with lower levels.
Researchers found that combining DHEA with red clover isoflavones increased testosterone production and reversed androgenic effects in prostate cells. The study suggests a potential cancer prevention effect of herbal supplements like DHEA, warranting further research.
A panel of small molecules, including sarcosine, has been identified as potential markers for aggressive prostate cancer. Sarcosine was found in higher levels in advanced prostate cancer samples and was a better indicator than traditional PSA test.
Researchers have identified a new biological marker, sarcosine, that indicates prostate cancer progression and spreading. Sarcosine levels increase in tumor cells and urine samples as the disease develops.
A new method uses circulating tumour cells to monitor disease status and predict survival in patients with advanced prostate cancer. Changes in CTC number before and after treatment are strongly associated with risk, making it a more predictive biomarker than PSA.
Researchers at Burnet Institute develop a potential new treatment for prostate cancer using a monoclonal antibody targeting the PIM-1 molecule, which plays a critical role in cell survival and proliferation. Laboratory models show significant inhibition of cancer cell growth, paving the way for clinical trials.
Research from Albert Einstein College of Medicine found that Ashkenazi Jewish men carrying specific gene mutations have a higher risk of developing aggressive prostate cancer. The study identified three particular mutations, including BRCA1-185delAG and the mutated BRCA2 gene, which increased the risk of high-grade tumors.
A study of over 800 men found that those who were very sexually active in their twenties and thirties were more likely to develop prostate cancer, especially if they masturbated frequently. However, the risks diminished with age, particularly in a man's fifties.
Researchers investigate thalidomide for biochemical recurrence and adjuvant radiotherapy for improved survival, reducing metastases risk by 29%. Both treatment options show promise for patients with biochemically recurrent prostate cancer after surgery.
Researchers have found that certain measles virus vaccine strain derivatives can effectively infect, replicate in and kill prostate cancer cells. This type of treatment, called virotherapy, shows promise as a potential cure for locally advanced or metastatic prostate cancer.
Researchers have discovered a key difference in hormone receptors on prostate cancer cells in patients who no longer respond to hormone deprivation therapy. The finding, published in Cancer Research, could lead to new targets for treating prostate cancer and monitoring disease progression.
A recent study by Charles Drew University found that gay and bisexual black men have the lowest use of prostate cancer testing. The percentage of gay and bisexual black men who received the PSA test was 12-28% lower than heterosexual blacks and 15-28% lower than gay and bisexual whites.
Researchers discovered that noscapine, an ingredient in common cough medication, reduced tumor growth by 60% and limited tumor spread by 65% without causing side effects. The findings suggest a promising treatment for advanced prostate cancer.
A recent study published in The Journal of Urology found that low-income men are diagnosed with more advanced prostate cancer due to inadequate access to screening services. This disparity is significant, as the study reveals that 19% of these men were diagnosed with metastatic cancer, compared to 4% in the general population.
A UCLA study found that low-income men are more likely to present with advanced prostate cancers, highlighting the need for increased access to screening services. The study also revealed that diagnosis rates for lower-risk cancers did not increase over time among IMPACT patients, unlike in more affluent populations.
In a phase III trial, combining endocrine treatment with radiotherapy reduced prostate cancer mortality by half compared to endocrine treatment alone. The study found significant superiority of the combined treatment over hormone therapy alone in reducing prostate cancer-specific mortality and overall survival.
The study found that the majority of men complied with PSA and DRE tests, with over 84% of diagnosed cancers picked up by screening. Cancer detected at baseline tended to be more serious and aggressive than those detected later.
A recent study led by Massachusetts General Hospital researchers found that hormone therapy for prostate cancer does not appear to increase the risk of death from cardiovascular disease. However, other adverse effects such as diabetes and heart disease still exist, necessitating careful treatment strategies.
A major study of over 14,000 male physicians found that long-term vitamin E and C supplementation had no significant impact on prostate cancer or total cancer risk. The study suggests that these supplements may not be effective in preventing cancer in middle-aged and older men.
A large cancer prevention trial found no association between supplementation with vitamin E or selenium and a reduced risk of prostate cancer. The study included 35,533 men and followed them for up to 7 years, concluding that these supplements were ineffective in preventing prostate cancer.
Researchers from Baylor College of Medicine found that prostate cancer promotes the growth of new nerves and axons, a phenomenon associated with more aggressive tumors. This discovery could lead to new targets for treatment, as neurogenesis is present in more aggressive cancers.
Researchers at USC have discovered a novel approach to suppressing prostate cancer development by inactivating a specific protein biomarker. By blocking the glucose-regulated protein GRP78, they found that prostate tumor progression can be halted in animal models.
African-American men and those with a family history of prostate cancer are at higher risk due to genetic factors. Genetic markers associated with increased risk have been found to be more prevalent in these populations, suggesting they may be used for personalized screening recommendations.
Researchers found that men taking aspirin had significantly lower PSA levels, especially among those with prostate cancer. However, this may affect the ability to detect early-stage prostate cancer through PSA screening.
A new cross-Canada study found that breast and prostate cancer treatment can cause significant bone loss, affecting up to 46,000 people each year. The researchers discovered that medications called bisphosphonates can help combat osteoporosis and fractures in cancer patients.
Popular cholesterol-busting drugs statins appear to lower men's PSA values along with their cholesterol levels. However, it remains unclear whether statins prevent prostate cancer growth or just mask it. The study found that PSA levels declined by an average of about four percent after starting statins.
A recent study found that statin use is associated with a decline in prostate-specific antigen (PSA) levels, suggesting potential benefits for prostate cancer screening and management. The study, which analyzed data from over 1,200 men, showed a median decline of 4.1% in PSA levels after starting statin therapy.
The Center for Minority Health (CMH) at the University of Pittsburgh School of Public Health has developed innovative programs to improve the health and well-being of racial and ethnic minorities, including a prostate cancer prevention program that trains barbers to deliver accurate health information. The organization also partnered w...
A new prostate cancer gene test using a urine sample has shown promising results in detecting the disease at an early stage. The test, PCA3, is highly specific to PCa and may allow patients to avoid unnecessary biopsies.
The US Preventive Services Task Force (USPSTF) recommends high-intensity behavioral counseling for all sexually active individuals at increased risk for STIs. The new stool DNA test is twice as effective at detecting colon cancer and polyps than previous tests, showing promise for improved screening effectiveness.
A substudy of the Physician's Health Study found that overweight men with high plasma concentrations of C-peptide, a protein reflecting insulin secretion, had significantly higher prostate-cancer mortality rates. Men with both high C-peptide and BMI prior to diagnosis had a four times higher risk of disease-specific mortality.
Researchers found that older men with high-risk prostate cancer who received hormone therapy lived longer and experienced fewer PSA increases compared to those without treatment. A longer duration of hormone therapy resulted in improved overall survival rates, especially among those over 70.
A new web site, CaP Calculator, provides cancer specialists with access to the latest research and helps them individualize patient treatment options. The tool allows doctors to evaluate the risk of disease spreading and the effectiveness of surgery and radiation treatment.
A large cohort study found that hormone therapy before radiation seed implants for prostate cancer increases the risk of death by 20% in men over 70 years old with early-stage cancer. This treatment approach may have negative effects on survival, particularly for older patients.
The American Urological Association has released a best practice statement on cryosurgery, recommending it as an option for men with clinically organ-confined prostate cancer. The panel of experts emphasized the importance of case selection and recommended maximizing results through temperature monitoring and double freeze cycles.
A randomized study found that adding radiation therapy to hormone treatment reduces the risk of dying from prostate cancer by 50% compared to hormone therapy alone. The quality of life at four years after treatment was similar between the two groups, with decreased social function in patients who received combined treatment.
Researchers found that genetic programs forming the prostate in embryos are similar to those driving tumor growth in prostate cancers. They identified genes involved in cell survival, growth, and movement that are activated in both normal development and aggressive prostate cancers.
Common painkillers such as aspirin and ibuprofen appear to lower a man's PSA level, the blood biomarker used to gauge prostate cancer risk. However, the study does not prove a direct link between the medications and reduced risk of prostate cancer.
Regular NSAID use can reduce serum PSA levels, potentially altering prostate cancer detection in individuals taking these medications. Chronic inflammation linked to prostate cancer may be masked by NSAIDs, which inhibit COX enzymes.
Researchers at Wake Forest University School of Medicine have found a second independent site within the HNF1B gene that may contribute to the risk of developing prostate cancer. The new discovery strengthens the link between genetic variants and prostate cancer risk, improving the ability to predict prostate cancer risk.
A study from Columbia University's Mailman School of Public Health found associations between smoking, obesity, and physical inactivity with lower Prostate Specific Antigen (PSA) awareness. This may lead to reduced prostate cancer screening rates among affected individuals.
Researchers have found that a common treatment for advanced prostate cancer can actually cause some cancer cells to grow, rather than stopping them. The androgen receptor plays a versatile role in the disease, acting as both a tumor promoter and suppressor in different cell types.
A randomized trial found that radical prostatectomy reduces prostate cancer death rates, with benefits lasting beyond 10 years. However, the applicability of these results to modern prostate cancer patients is unclear due to the widespread use of PSA screening.
A study published by researchers at Duke University Medical Center found that only one-fifth of men under age 50 reported undergoing a PSA test in the previous year. Black men and men with a family history are disproportionately affected, highlighting the need for increased awareness and screening efforts.
A study found that one in five men in their 40s have undergone a PSA test within the previous year. Young black men are more likely than young white men to have been screened. The study also revealed that younger Hispanic men and those with higher household income and education level were more likely to undergo testing.
Research finds that PSA screening can lead to delayed diagnosis and more aggressive cancer outcomes for obese men. The study suggests that alternative screening methods or lower threshold for worrisome PSA levels may be necessary for this population.
Research shows Vietnam War veterans exposed to Agent Orange have increased risks of prostate cancer and aggressive forms of the disease compared to those not exposed. The study, conducted on over 13,000 men in their 60s, found twice as many exposed veterans developed prostate cancer.
The USPSTF recommends against routine prostate cancer screening for men over 75 due to insufficient scientific evidence showing improved health outcomes. Men under 75 may benefit from screening with more evidence needed, according to the updated recommendations.